Levocetirizine in persistent allergic rhinitis: Continuous or on-demand use? A pilot study

Current Medical Research and Opinion

Volumn 24, Issue 10, 2008, Pages 2829-2839

  Canonica, Giorgio Walter ^a   Fumagalli, Federica ^a   Guerra, Laura ^a   Baiardini, Ilaria ^a   Compalati, Enrico ^a   Rogkakou, Anthi ^a   Massacane, Pierangela ^a   Gamalero, Cinzia ^a   Riccio, Anna Maria ^a   Scordamaglia, Antonio ^a   Passalacqua, Giovanni ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Antihistamine; Continuous; Levocetirizine; On demand; Persistent allergic rhinitis

Indexed keywords

CROMOGLYCATE DISODIUM; LEVOCETIRIZINE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CONTROL; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; DRUG WITHDRAWAL; EPISTAXIS; FEMALE; HUMAN; HUMAN TISSUE; INFLAMMATION; INFLUENZA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; NASAL PRURITUS; NOSE SMEAR; OPEN STUDY; PERENNIAL RHINITIS; PHASE 4 CLINICAL TRIAL; PILOT STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SLEEP; SOMNOLENCE; SYMPTOMATOLOGY; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; CETIRIZINE; FEMALE; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; PILOT PROJECTS; QUALITY OF LIFE; RHINITIS, ALLERGIC, PERENNIAL; TIME FACTORS;

EID: 55549101948     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/03007990802395927     Document Type: Article

References (33)

1. Bousquet J, van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001;108 (5 Suppl):S147-334
2. Schoenwetter WF, Dupclay L, Appajosyula S, et al. Economic impact and quality of life burden of allergic rhinitis. Curr Med Res Opin 2004;20:305-17
3. Blanc PD, Trupin L, Eisner M, et al. The work impact of asthma and rhinitis: findings from a population-based survey. J Clin Epidemiol 2001;54:610-18
4. Bousquet J, Annesi-Maesano I, Carat F, et al. Characteristics of intermittent and persistent allergic rhinitis: DREAMS study group. Clin Exp Allergy 2005;35:728-32
5. Bousquet J, Neukirch F, Bousquet PJ, et al. Severity and impairment of allergic rhinitis in patients consulting in primary care. J Allergy Clin Immunol 2006;117:158-62
6. Mösges R, Klimek L. Today's allergic rhinitis patients are different: new factors that may play a role. Allergy 2007;62:969-975
7. Passalacqua G, Ciprandi G, Pasquali M, et al. An update on the asthma-rhinitis link. Curr Opin Allergy Clin Immunol. 2004; 4:177-83
8. Bachert C, van Cauwenberge P, Olbrecht J, et al. Prevalence, classification and perception of allergic and nonallergic rhinitis in Belgium. Allergy 2006;61:693-8
9. Bauchau V, Durham SR. Epidemiological characterization of the intermittent and persistent types of allergic rhinitis. Allergy 2005;60:350-3
10. Demoly P, Allaert F-A, Lecasble M, et al. PRAGMA. Validation of the classification of ARIA (allergic rhinitis and its impact on asthma). Allergy 2003;58:672-5
11. Ciprandi G, Buscaglia S, Pesce GP, et al. Minimal persistent inflammation is present at mucosal level with asymptomatic rhinitis and mite allergy. J Allergy CJin Immunol 1995;96:971-9
12. Ricca V, Landi M, Ferrero C, et al. Minimal persistent inflammation is also present in patients with seasonal allergic rhinitis. J Allergy Clin Immunol 2000-105(1 Pt 1):54-7
13. Strolin-Benedetti M, Plisnier M, Kaise J, et al. Absorption, distribution, metabolism and excretion of [14C] levocetirizine, the R enantiomer of cetirizine, in healthy volunteers. Eur J Clin Pharmacol 2001;57:571-82
14. Molimard M, Diquet B, Strolin Benedetti M. Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans. Fundam Clin Pharmacol 2004;18:399-411
15. 1-antihistamines. Inflamm Res 2005;54:367-9
16. Hair PI, Scott RJ. Levocetirizine: a review of its use in the management of allergic rhinitis and skin allergies. Drugs 2006; 66:973-96
17. Bachert C, Bousquet J, Canonica GW, et al. Levocetirizine improves quality of life and reduces costs in long-term management of persistent allergic rhinitis. J Allergy Clin Immunol 2004;114:838-44
18. Canonica GW, Bousquet J, Van Hammee G, et al. Levocetirizine improves health-related quality of life and health status in persistent allergic rhinitis. Respir Med 2006; 100:1706-15
19. Baiardini I, Pasquali M, Giardini A, et al. Rhinasthma: a new specific Qol Questionnaire for the subjects with rhinitis and asthma. Allergy 2003;58:289-94
20. Ciprandi G, Pronzatc, C, Ricca V, et al. Terfenadine exerts anti-allergic activity reducing ICAM-1 expression on nasal epithelial cells in subjects with pollen allergy. Clin Exp Allergy 1995; 25:871-8
21. de Blic J, Wahn U, Billard E, et al. Levocetirizine in children: evidenced efficacy and safety in a 6-week randomized seasonal allergic rhinitis trial. Pediatr Allergy Immunol 2005; 16:267-75
22. Potter PC. Levocetirizine is effective for symptom relief including nasal congestion in adolescent and adult (PAR) sensitized to house dust mites. Allergy 2003;58:893-9
23. Potter PC. Efficacy and safety of levocetirizine on symptoms and health-related quality of life of children with perennial allergic rhinitis: a double-blind, placebo-controlled randomized clinical trial. Ann Allergy Asthma Immunol 2005; 95:175-80
24. Ciprandi G, Passalacqua G, Mincarini M, et al. Continuous versus on demand treatment cetirizine for allergic rhinitis. Ann Allergy Asthma Immunol 1997;79:507-11
25. Ciprandi G, Ricca V, Passalacqua G, et al. Seasonal rhinitis and azelastine: long- or short-term treatment? J Allergy Clin Immunol 1997;99:301-7
26. Ciprandi G, Marseglia GL, Klersy C, et al. Relationships between allergic inflammation and nasal airflow in children with persistent allergic rhinitis due to mite sensitization. Allergy 2005;60:957-60
27. Lauriello M, Muzi P, Di Rienzo L, et al. A two-year course of specific immunotherapy or of continuous antihistamine treatment reverse eosinophilic inflammation in severe persistent allergic rhinitis. Acta Otorhinolaryngol Ital 2005; 25:284-91
28. Baiardini I, Brandi S, Braido F, et al. Allergic diseases and their impact on quality of life. Ann Allergy Asthma Immunol 2006; 97:419-28
29. Stull DE, Roberts L, Frank L, et al. Relationship of nasal congestion with sleep, mood, and productivity. Curr Med Res Opin 2007;23:811-19
30. Pratt EL, Craig TJ. Assessing outcomes from the sleep disturbance associated with rhinitis. Curr Opin Allergy Clin Immunol 2007;17:249-56
31. Klimek L, Bachert C, Canonica GW, et al. Long-term treatment of persistent allergic rhinitis with levocetirizine: improvements in activity and sleep items of the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ). Allergy Clin Immunol Int - J World Allergy Org 2007;19:4-10
32. Pasquali M, Baiardini J, Rogkakou A, et al. Levocetirizine in persistent allergic rhinitis and asthma: effects on symptoms, quality of life and inflammatory parameters. Clin Exp Allergy 2006;36:1161-7
33. Ciebiada M, Górska-Ciebiada M, DuBuske LM, et al. Montelukast with desloratadine or levocetirizine for the treatment of persistent allergic rhinitis. Ann Allergy Asthma Immunol 2006;97:664-71